Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrodin as bridging therapy for medication overuse headache
ChiCTR2200063719Phase 4Not yet recruiting
- Sponsor
- Second People's Hospital of Yunnan Province
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gastrodin in medication overuse headache (MOH) (2 arms), sponsored by Second People's Hospital of Yunnan Province. Primary endpoints: Reduction in mean number of monthly headache days from baseline and Proportion of cured medication overuse headache at week 24. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
gastrodin
03
Conditions
medication overuse headache (MOH)
Beyond the preview
Go deeper on ChiCTR2200063719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063719.